English | Español

Biospace
+ Pharmaceuticals
Patient Daily | Jan 7, 2026

Pfizer leads U.S. drugmakers in planned price increases for 2026
+ Pharmaceuticals
Patient Daily | Jan 7, 2026

FDA approves Vanda's Nereus as first new motion sickness drug in four decades
+ Pharmaceuticals
Patient Daily | Jan 7, 2026

BioSpace announces NextGen Class of 2026 highlighting top biotech startups
+ Pharmaceuticals
Patient Daily | Jan 6, 2026

Biotech IPO activity slows sharply in 2025 as investor scrutiny increases
+ Pharmaceuticals
Patient Daily | Jan 6, 2026

FDA increasingly diverged from advisory panel advice while holding fewer meetings in 2025
+ Pharmaceuticals
Patient Daily | Jan 6, 2026

Pharma faces continued uncertainty over drug pricing despite most favored nation deals
+ Pharmaceuticals
Patient Daily | Jan 6, 2026

Trump administration reduces childhood vaccination recommendations; industry reacts
+ Pharmaceuticals
Patient Daily | Jan 6, 2026

Arrowhead reports promising early trial results combining RNAi therapy with tirzepatide for obesity

Trending
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
+ Pharmaceuticals
Patient Daily | Aug 4, 2026

Merck reports mixed results for tulisokibart in recent clinical trials and financial update
+ Regulatory
M. Y. Bailey | Aug 7, 2026

PhRMA's Zirkelbach: 340B program has changed dramatically with 'little transparency into how patients benefit'
Patient Daily reports | Aug 10, 2026

SoCal Breathe Free warns persistent sinus symptoms may signal chronic inflammation